IKBKB

IKBKB

A gene on chromosome 8p11.2 that encodes a serine kinase which plays a key role in the NF-kappa-B signalling pathway by phosphorylating inhibitors in the inhibitor/NF-kappa-B complex (comprised of 3 subunits: IKBKA (IKKalpha/IKK1), IKBKB (IKKbeta/IKK2) and IKBKG (NEMO)), causing inhibitor dissociation and NF-kappa-B activation. The NF-kappa-B signalling pathway is activated by multiple stimuli, including inflammatory cytokines, bacterial or viral products, DNA damage, or other cellular stresses.
References in periodicals archive ?
The stretch responsive microRNA miR-148a-3p is a novel repressor of IKBKB, NF-kappaB signaling, and inflammatory gene expression in human aortic valve cells.
Additionally, upregulation of mitogen-activated protein kinase (MAPK) [32] and inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (Ikbkb) [33] and downregulation of mammalian target of rapamycin (mTOR) [34] and protein kinase C, zeta (Prkcz) [35], as seen with the untreated control group (Figure 6) are thought to promote phosphorylation of IRS with consequent increase in insulin resistance due to disruption of IRS-mediated insulin action via activation of PI3K [28, 30].
Ikbkb: Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Comparison of Genetic Aberrations in Splenic Small B-Cell Lymphomas (a) Variable Gene Mutation Associated Structural Abnormality SMZL NOTCH2 (~25%) del 7q (~45%); Less NF-[kappa]B pathwa commonly: trisomy (BIRC3, TNFAIP3, 3, trisomy 12, MAP3K14, IKBKB) trisomy 18, 17p (~33%) (TP53) Rare: MYD88 L265P SDRPL Unknown Uncommon: del 7q, trisomy 18, del 17p (TP53) HCL-v MAP2K1 (~33%) del 17p (TP53) (~33%); Uncommon: 5q gain, del 7q HCL BRAF V600E (>90%) Rare: 5q gain, del 7q LPL MYD88 L265P (~90%) del 6q (~45%); Uncommon: del 13q, del 7q Abbreviations: HCL, hairy cell leukemia; HCL-v, hairy cell leukemia variant; LPL, lymphoplasmacytic lymphoma; NF-[kappa]B, nuclear factor-[kappa]B; SDRPL, splenic diffuse red pulp small B-cell lymphoma; SMZL, splenic marginal zone lymphoma.
Module Drug Drug Drug class target (2) JAK1 Tofacitinib DMARDs JAK2 Tofacitinib DMARDs (4) IL1B Canakinumab Biotech agents IL6R Tocilizumab Biotech agents LTA Etanercept Biotech agents Etanercept Biotech agents Adalimumab Biotech agents TNF Infliximab Biotech agents Golimumab Biotech agents Certolizumab pegol Biotech agents Chloroquine DMARDs TNFRSF1B Etanercept Biotech agents (5) IL1R1 Anakinra Biotech agents (6) PTK2B Leflunomide DMARDs (7) MAPK3 Sulindac NSAIAs CHUK Sulfasalazine DMARDs (8) IKBKB Sulfasalazine DMARDs Auranofin DMARDs (9) PDPK1 Celecoxib NSAIAs (10) BCL2 Ibuprofen NSAIAs
Fuchs et al., "Deficiency of innate and acquired immunity caused by an IKBKB mutation," The New England Journal of Medicine, vol.
In addition, selected miRNAs could also control DEGs involved in the innate immune response including, for example, NKTR (hsa-miR-181a-5p, -486-5p, -151-3p, and -27b-3p), KIR2DL4 (hsa-miR-146a-5p), STAT1 (hsa-miR584-5p, -27b-3p, -128-3p, and -146a-5p), STAT2 (hsa-miR143-3p), and DEGs belonging to the Toll-like receptor (TLR) pathway such as TLR2, IKBKB, JUN, REL, NAMPT, HSP90B1, HSPA4, and ARF3.
Hollands et al., "The stretch responsive microRNA miR-148a-3p is a novel repressor of IKBKB, NF-[kappa]B signaling, and inflammatory gene expression in human aortic valve cells," FASEB Journal, vol.